Concept and Objectives Capacity and Resources Who We Are Events, Awards and Funding Contact
MalVa GmbH is a spin-off company of the University Hospital Heidelberg, Germany, founded in May 2011.
MalVa specialises in Malaria vaccine development employing novel not yet described malarial pre-erythrocytic antigens. These antigens are currently tested in immunological and vaccination studies. We aim to develop our MalVaccine towards a phase II clinical trial. Collaborative development and licensing agreements with an experienced pharmaceutical company will bring the product to the market.